semaglutide weight loss injections for women spokane Amazon launches drug program Ozempic Weight Loss Injections &

In December 2025, CMS announced the Medicare GLP-1 Bridge demonstration, a short-term program that will allow eligible Medicare beneficiaries to access GLP-1 obesity medications at a $50/month co-pay starting July 2026 , using a centralized processor to manage PA, claims adjudication, and payment ( [18] )

Growth hormone secretagogues like sermorelin are a preferred option for most anti-aging patients

Tau accumulation activates the unfolded protein response by impairing endoplasmic reticulum-associated degradation

TRANSCEND-T2D-1: The Diabetes-Specific Program (June 2026) Separate from the TRIUMPH obesity program, Eli Lilly is running TRANSCEND-T2D a dedicated three-trial Phase 3 program focused specifically on type 2 diabetes